7 completed, 2 recruiting, 1 terminated, 1 unknown. 3 Not applicable, 3 Phase 1, 3 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 3 | Completed 1, Recruiting 1, Unknown 1 |
| Phase 1 | 3 | Completed 2, Terminated 1 |
| Phase 2 | 3 | Completed 2, Recruiting 1 |
| Phase 3 | 2 | Completed 2 |
Follow Hypertension, Essential: new trials by email Literature Review of Hypertension, Essential trials Research Report on Hypertension, Essential
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of SPC1001 in Patients With Essential Hypertension SPC 1001 Mid2, SPC 2002, SPC 2003 - Hypertension, Essential, Cardiovascular Diseases | Phase 2 | Recruiting | Shin Poong Pharmaceutical Co. Ltd. | 252 | 2024-06-12 | 2025-02-14 |
| BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated, Medtronic Astra/Azure DR MRI IPG with AVIM therapy Deactivated - Hypertension, Hypertension, Systolic | Not applicable | Recruiting | Orchestra BioMed, Inc | 316 | 2023-12-27 | 2026-10-02 |
| A Study to Evaluate the Efficacy and Safety of AD-209 AD-209, AD-209-1A, AD-209-1B - Hypertension, Essential | Phase 2 | Completed | Addpharma Inc. | 221 | 2023-04-05 | 2024-04-05 |
| Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022 AD-2021, AD-2022, AD-2021 Placebo - Hypertension, Essential, Primary Hypercholesterolemia | Phase 3 | Completed | Addpharma Inc. | 109 | 2020-10-22 | 2024-06-07 |
| The Association Between Serum β-hydroxybutyrate and Levels of Systemic Hypertension dietary restriction (salt restriction) - Hypertension, Essential, β-hydroxybutyrate | Not applicable | Unknown | Sulaiman AlRajhi Colleges | 100 | 2020-04-15 | 2020-04-02 |
| Effects of TENS and IES on the Autonomous Balance of Normotens Volunteers and Hypertensive Patients Transcutaneous nervous electric stimulation (TENS), Interferential electrical stimulation (IES), TENS and IES Placebo - Healthy Volunteers, Hypertension, Essential | Not applicable | Completed | Universidade Federal de Santa Maria | 60 | 2018-07-20 | 2019-12-11 |
| Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension Angiotensin (1-7), Trimethaphan, Phenylephrine - Hypertension, Hypertension, Essential | Phase 1 | Terminated | Vanderbilt University | 24 | 2015-01-01 | 2024-01-09 |
| Efficacy and Safety of Fimasartan Alone or Combined With HCTZ in Mexican Patients With Essential Hypertension Fimasartan, Fimasartan; Hydrochlorothiazide - Hypertension, Essential | Phase 3 | Completed | Stendhal Americas, S.A. | 272 | 2013-04-01 | 2015-06-09 |
| Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension Candesartan cilexetil (Atacand), 4 mg, Candesartan cilexetil (Atacand), 8 mg, Nifedipine GITS (Adalat, BAYA1040), 20 mg - Hypertension, Essential | Phase 2 | Completed | Bayer | 1381 | 2011-04-01 | 2017-04-18 |
| Pivotal Bioequivalence FDC Nifedipine / Candesartan vs. Loose Combination of Single Components, Fed Nifedipine/Candesartan (BAY 98-7106), Nifedipine (Adalat, BAY A1040) and Candesartan (Atacand, BAY 12-9333) - Hypertension, Essential | Phase 1 | Completed | Bayer | 49 | 2011-04-01 | 2015-12-10 |
| Single Dose Bioequivalence Study Comparing Nifedipine/Candesartan FDC (Fixed Dose Combination) With Loose Combination of Nifedipine GITS (Gastro-intestinal Therapeutic System) Plus Candesartan and Single Components Under Fasting Conditions Nifedipine-candesartan FDC (BAY 98-7106), Nifedipine GITS (Adalat LA, BAYA1040), Candesartan (Atacand) - Hypertension, Essential | Phase 1 | Completed | Bayer | 49 | 2010-11-01 | 2015-12-10 |
Essential Hypertension (11) · Hypertension (3) · Cardiovascular Diseases (1) · Isolated Systolic Hypertension (1)
Vascular Diseases (11) · Cardiovascular Diseases (10) · Hypertension (8)
Nifedipine (3) · candesartan cilexetil (3) · candesartan (2) · Diet Therapy (1) · Hydrochlorothiazide (1) · Phenylephrine (1) · Transcutaneous Electric Nerve Stimulation (1) · Trimethaphan (1) · angiotensin I (1-7) (1) · fimasartan (1) · trimethaphan camsylate (1)
Bayer (3) · Addpharma Inc. (2) · Orchestra BioMed, Inc (1) · Shin Poong Pharmaceutical Co. Ltd. (1) · Stendhal Americas, S.A. (1) · Sulaiman AlRajhi Colleges (1) · Universidade Federal de Santa Maria (1) · Vanderbilt University (1)
South Korea (4) · Germany (3) · United States (3) · Belgium (2) · Brazil (2) · Italy (2) · Spain (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Canada (1) · China (1) · Czechia (1) · France (1) · Hungary (1)
Andrea Russo, MD (1) · Chang Gyu Park, M.D., Ph.D (1) · David Kandzari, MD (1) · Hossam Sherif, MD (1) · Ignacio Conde-Carmona, M.D. (1) · Italo Biaggioni, MD (1) · Seok Min Kang, M.D., Ph.D (1)
PMID 15539615, PMID 16672842, PMID 21827970, PMID 21910510, PMID 22262107, PMID 22381711, PMID 22608107, PMID 23004921, PMID 23344912, PMID 23849325, PMID 23932463, PMID 23966145, PMID 25144296, PMID 26829251
2009 (1)